<DOC>
	<DOCNO>NCT00925275</DOCNO>
	<brief_summary>The purpose study investigate safety , biodistribution , radiation dosimetry pharmacokinetics I-131-CLR1404 .</brief_summary>
	<brief_title>Dosimetry Study I-131-CLR1404 Patients With Relapsed Refractory Advanced Solid Tumors</brief_title>
	<detailed_description>I-131-CLR1404 small-molecule , phospholipid ether analog combine lipid-like property cancer therapeutic beta-emitting radioisotope . Cellectar believe compound benefit individual cancer due selective retention accumulation malignant cell versus nonmalignant cell . Preclinical experiment demonstrate I-131-CLR1404 significantly slow malignant tumor growth several mouse tumor model .</detailed_description>
	<criteria>Relapsed refractory advance solid tumor ( ) exhaust standard treatment option standard therapy exists Must sufficient window time complete washout period , dosimetry data acquisition follow safety assessment period ECOG performance status 0 1 estimate life expectancy ≥ 4 month 18 year old Must compliant protocol within geographical proximity make require study visit Have ability read , understand provide write informed consent Patients brain metastasis acceptable clinical condition stable least one month Female patient childbearing potential must negative serum pregnancy test within 24 hour start treatment Must agree use effective method contraception study 90 day follow last dose study drug Patient physician plan concomitant chemotherapy , therapeutic radiation treatment , and/or biological treatment cancer include immunotherapy study More 25 % total bone marrow irradiate Diffuse lung disease interstitial spread carcinoma Bladder rectum within prior radiation therapy field dose great 45 Gy administer Total therapeutic radiation dose past year excess 25 Gy kidney , 45 Gy brain , 45 Gy stomach , 18 Gy lung , 25 Gy liver Prior totalbody irradiation Extradural tumor contact spinal cord , tumor locate swell response therapy may impinge upon spinal cord Prior radiation therapy chemotherapy within 2 week start study Active medical condition ( ) organ disease ( ) may either compromise patient safety interfere safety and/or outcome evaluation study drug Laboratory value ≤ 7 day : WBC &lt; 3000/µL Absolute neutrophil count &lt; 1500/µL Platelets &lt; 150,000/µL Hemoglobin ≤ 11.0 gm/dL Total bilirubin &gt; 1.5 x upper limit normal age SGOT SGPT &gt; 3 x upper limit normal age liver metastases &gt; 5 x upper limit normal age presence liver metastases Serum creatinine &gt; 1.5 x upper limit normal age INR ≥ 2.0 Investigational drug , investigational biologic , investigational therapeutic device within 30 day initiate study drug Severely marrow toxic drug ( e.g . nitrosoureas , mitomycin ) Prior treatment Iodine131 past five year Concurrent hemodialysis Blood transfusion within 60 day study start Hematopoietic growth factor therapy within 60 day study start Prior stem cell transplantation Clinically evident ascites peritoneal carcinomatosis Clinically significant cardiac comorbidities include : CHF , LVEF &lt; 40 % , unstable angina pectoris , serious cardiac arrhythmia require medication pacemaker , myocardial infarction within past six month Clinically significant pulmonary impairment define SaO2 room air 93 % le Concurrent recent use thrombolytic agent , fulldose anticoagulant Uncontrolled hypertension patient uncontrolled diabetes Grade IIIV peripheral vascular disease peripheral vascular surgery within past year Less 4 week since prior major surgery Known positive HIV , Hepatitis C ( active , previously treat ) , Hepatitis B core antigen positive Concurrent chronic use aspirin ( 325 mg/day ) Pregnant lactate Patients colostomy/ileostomy Poor venous access Prior allergic reaction iodine , study agent Significant traumatic injury within past 4 week Ongoing active infection require antibiotic fever &gt; 38.1°C ( &gt; 101° F ) within 3 day first schedule day dose Patients hospitalize</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Refractory</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Radiation</keyword>
	<keyword>Dosimetry</keyword>
	<keyword>Radiopharmaceutical</keyword>
	<keyword>Biodistribution</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Cancer</keyword>
	<keyword>Phase I</keyword>
</DOC>